With respect to safety concerns, the critical appraisal of available evidence suggests that poor baseline glucose control and insulin reserve increase the risk of adverse events, especially hyperglycemia, ketosis, and gastrointestinal discomfort, leading to GLP‐1RA intolerance, frequent dose de‐escalation, or early discontinuation. Here, INS is linked to Hyperglycemia.